Propath has announced a strategic partnership with Visiopharm to provide advanced multiplex image analysis services, further strengthening its end‑to‑end spatial biology offering.
As multiplex immunofluorescence (mIF) studies continue to generate increasingly complex, high‑plex datasets, robust quantitative image analysis has become essential for extracting meaningful biological insight. Through this collaboration, Propath integrates Visiopharm’s industry-leading image analysis capabilities with its established expertise in tissue processing, assay development, and molecular pathology.
The partnership enables standardised, reproducible quantification of spatial data, supporting applications such as immune profiling, biomarker discovery, and mechanism‑of‑action studies. By combining high‑quality wet-lab workflows with advanced analytics, Propath can deliver reliable, data-rich outputs to support translational research and clinical development programmes.
Click here to learn more about Propath's services for multiplex image analysis.
